Literature DB >> 28906023

Immunophenotypic and molecular comparison between allogeneic and autologous graft-vs-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods.

Julia S Lehman1,2, Shahrukh K Hashmi3, Hillard M Lazarus4, Rokea A El-Azhary1, Lawrence E Gibson1,2, William J Hogan3, Mark R Litzow3, Mrinal S Patnaik3, Francis Buadi3, Martha Q Lacy3, Surendra Dasari5, Patrick Vanderboom6, Alexander Meves1.   

Abstract

Entities:  

Keywords:  graft-vs-host disease; immunity; interferon; proteomics; vacuolar interface dermatitis

Mesh：

Year:  2017        PMID： 28906023      PMCID： PMC5942197          DOI： 10.1111/cup.13019

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN： 0303-6987            Impact factor:   1.587


× No keyword cloud information.
  16 in total

1.  Autologous GVHD?

Authors:  F Otegbeye; R P Gale; H M Lazarus
Journal:  Bone Marrow Transplant       Date:  2014-08-04       Impact factor: 5.483

2.  A pilot study comparing histological and immunophenotypic patterns in stage 4 skin graft vs host disease from toxic epidermal necrolysis.

Authors:  Haley Naik; Stephen Lockwood; Arturo Saavedra
Journal:  J Cutan Pathol       Date:  2017-07-19       Impact factor: 1.587

3.  Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD.

Authors:  Y Miura; C J Thoburn; E C Bright; M Sommer; S Lefell; M Ueda; S Nakao; A D Hess
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

4.  Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.

Authors:  Rondell P Graham; Luigi M Terracciano; Alexander Meves; Patrick M Vanderboom; Surendra Dasari; Matthew M Yeh; Michael S Torbenson; Michael W Cruise
Journal:  Mod Pathol       Date:  2016-03-25       Impact factor: 7.842

5.  IL-22 promoted CD3+ T cell infiltration by IL-22R induced STAT3 phosphorylation in murine acute graft versus host disease target organs after allogeneic bone marrow transplantation.

Authors:  Kai Zhao; Suhong Ruan; Yu Tian; Dongmei Zhao; Chong Chen; Bin Pan; Zhiling Yan; Lingling Yin; Shengyun Zhu; Kailin Xu
Journal:  Int Immunopharmacol       Date:  2016-08-20       Impact factor: 4.932

6.  MxA expression in patients with viral infection after allogeneic stem cell transplantation.

Authors:  T Yoshimasu; A Manabe; Y Ebihara; R Tanaka; J Ooi; T Iseki; N Shirafuji; T Maekawa; S Asano; N Yoshikawa; K Tsuji
Journal:  Bone Marrow Transplant       Date:  2003-08       Impact factor: 5.483

7.  Interferon alpha/beta synthesis during acute graft-versus-host disease.

Authors:  V E Reyes; G R Klimpel
Journal:  Transplantation       Date:  1987-03       Impact factor: 4.939

8.  The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.

Authors:  A-L Joly; A Deepti; A Seignez; A Goloudina; S Hebrard; E Schmitt; S Richaud; E Fourmaux; A Hammann; A Collura; M Svrcek; G Jego; E Robinet; E Solary; O Demidov; E Kohli; C Garrido
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

Review 9.  An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis".

Authors:  Joerg Wenzel; Thomas Tüting
Journal:  J Invest Dermatol       Date:  2008-04-17       Impact factor: 8.551

Review 10.  The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.

Authors:  Hui Wang; Yong-Guang Yang
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988
View more
  1 in total

1.  Differential expression of interferon-induced genes and other tissue-based biomarkers in acute graft-versus-host disease vs. lupus erythematosus in skin.

Authors:  J S Lehman; S Dasari; S S Damodaran; R A El-Azhary; L E Gibson; S K Hashmi; W J Hogan; S J Kenderian; M S Patnaik; M R Litzow; H M Lazarus; A Meves
Journal:  Clin Exp Dermatol       Date:  2018-10-02       Impact factor: 3.470
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.